What Each Treatment Is
Generic compounded ketamine refers to racemic ketamine (a mixture of both the S and R enantiomers) prepared by compounding pharmacies in sublingual tablet, troche, or lozenge form. This is the formulation used by virtually all telehealth ketamine providers. It is prescribed off-label for depression, anxiety, PTSD, and other conditions, meaning the FDA has not specifically approved this formulation for these indications, though the medication itself has been FDA-approved as an anesthetic since 1970.
Spravato (esketamine) is an FDA-approved nasal spray containing only the S-enantiomer of ketamine. It received FDA approval in 2019 specifically for treatment-resistant depression in adults and, subsequently, for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior. Spravato carries a specific Risk Evaluation and Mitigation Strategy (REMS) that requires administration in a certified healthcare setting.
Administration and Access
Generic ketamine via telehealth is administered at home. After a virtual evaluation, the medication is shipped from a compounding pharmacy directly to the patient. Treatment sessions are self-administered (with or without remote clinical supervision depending on the provider). This model offers maximum convenience and geographic accessibility. For a complete overview of the at-home process, see how telehealth ketamine works.
Spravato must be administered in a certified healthcare facility — a doctor's office, clinic, or hospital that has enrolled in the Spravato REMS program. Patients self-administer the nasal spray under the observation of a healthcare provider, then remain at the facility for at least two hours of monitoring after each dose. Spravato cannot legally be taken home or administered without in-person supervision.
This REMS requirement means Spravato is not available via telehealth. Patients must travel to a certified facility for every treatment session.
Cost Comparison
The cost difference between these options is dramatic. Generic compounded ketamine through telehealth programs typically costs $129-$400 per month, depending on the provider and treatment frequency. This includes medication, consultations, and varying levels of clinical support.
Spravato's wholesale cost is approximately $590-$885 per session (depending on the dose), not including facility fees, provider time, and monitoring costs. Without insurance, total per-session costs can exceed $1,000. However, Spravato has a significant advantage: as an FDA-approved medication, it is covered by many insurance plans, and the manufacturer offers a patient assistance program. For a deeper look at payment options for generic ketamine, see our insurance coverage guide. With insurance, patient out-of-pocket costs may be substantially lower.
Insurance Coverage
This is where the distinction matters most for many patients. Generic compounded ketamine prescribed off-label through telehealth is almost never covered by health insurance. Patients pay out of pocket, though HSA and FSA funds may be used.
Spravato, as an FDA-approved treatment, is covered by many commercial insurance plans, Medicare, and some Medicaid programs. Prior authorization is typically required, and patients generally must demonstrate treatment resistance (failure of at least two adequate antidepressant trials). The manufacturer also offers a co-pay assistance program for eligible commercially insured patients.
Clinical Evidence
Both treatments have robust clinical evidence supporting their efficacy, though through different channels.
Spravato's evidence base consists of the randomized controlled trials submitted to the FDA for approval, including pivotal trials published in peer-reviewed journals demonstrating statistically significant improvement in depression symptoms compared to placebo.
Generic racemic ketamine has a broader research history, with decades of clinical studies across multiple administration routes. The sublingual at-home model specifically has a growing evidence base, though most studies are observational rather than the large randomized controlled trials that supported Spravato's approval.
Some researchers argue that racemic ketamine (containing both enantiomers) may offer therapeutic advantages over esketamine alone, as the R-enantiomer may contribute to antidepressant effects through distinct mechanisms. However, this remains an active area of investigation.
References
- FDA Approval of Spravato for Treatment-Resistant Depression — FDA announcement and safety information for Spravato
- Comparative Efficacy of Racemic Ketamine and Esketamine — Research comparing the two ketamine formulations for depression treatment
- NIMH Research on Ketamine for Depression — NIMH-funded research on ketamine's antidepressant mechanisms
- Mayo Clinic Overview of Esketamine — Mayo Clinic clinical reference for esketamine nasal spray
Verdict
Generic compounded ketamine is more widely available through telehealth, significantly more affordable, and offers flexible dosing — but it is prescribed off-label and typically not covered by insurance. Spravato is FDA-approved for treatment-resistant depression with insurance coverage potential, but it must be administered in a certified healthcare facility under direct supervision. Patients prioritizing affordability and convenience may prefer generic ketamine via telehealth, while those with insurance coverage and a preference for FDA-approved treatments may benefit from Spravato through a certified clinic.
Share